Fundraising Fox

Tempothera

San Diego, US · Founded 2014 · Delaware corporation · 15 employees on LinkedIn · 1 known investors

Tempo Therapeutics is a biotechnology company developing therapeutics, with a focus that includes dermatology. Its team works on a pipeline built around its underlying technology platform.

BiotechHealthtechMedical Devices

Founders & leadership

Tempothera was founded in 2014 by Westbrook Weaver and Donald Griffin.

WWWestbrook Weaver
Westbrook WeaverFounder & CEO
DGDonald Griffin
Donald GriffinFounder & CSO
SDStephanie Deshayes
Stephanie DeshayesVP R&D
KU
Kwame UlmerChief Regulatory Officer
PSPhilip Scumpia
Philip ScumpiaVP of Medical Affairs, Dermatology
SR
Steven RichieriNamed on SEC filing
RH
Richard HancockNamed on SEC filing
DD
Dino Di CarloNamed on SEC filing

Investors · 1

Sugati VenturesSan Ramon

Reported raises · per SEC filings

Form D private placements

$20.2M disclosed across 2 rounds · 2015–2024

▶$16.3MraisedMar 2024 · 26 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Richard HancockDirector
  • Donald GriffinDirector
  • Steven RichieriDirector
  • Robin SitverDirector
  • Steven SandsDirector
  • Biren MehtaDirector
  • Westbrook WeaverExecutive Officer, Director
Offering amount
$16.8M
Amount sold
$16.3M
First sale
Mar 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.8MraisedAug 2021 · 39 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Westbrook WeaverExecutive Officer, Director, Promoter
  • Steven RichieriExecutive Officer, Director
  • Richard HancockDirector
  • Dino Di CarloDirector
  • Donald GriffinDirector
Offering amount
$3.9M
Amount sold
$3.8M
First sale
Jul 2015
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap
Mozart Therapeutics6 shared keywordsMozart Therapeutics develops protein therapeutics focused on immunology and oncology treatments. The company is founded on research from Stanford University scientists and is led by experienced biopharmaceutical industry executives.
Tempest Therapeutics6 shared keywordsTempest Therapeutics is a clinical-stage biotechnology company developing in vivo CAR-T cell therapies for autoimmune and oncology indications. Its pipeline includes a dual-target CD19/BCMA CAR structure and a CD7-targeted mRNA lipid nanoparticle CAR-T delivery platform, with lead candidate TPST-4003 planned for trials in myasthenia gravis and multiple sclerosis.

Companies competing with Tempothera for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 5 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Science FoundationPhase IISTTR2023$1M
National Institutes of Health (NIH)National Institutes of HealthPhase II2021$2.5M
National Science FoundationPhase I2020$256K
National Institutes of Health (NIH)National Institutes of HealthPhase II2019$1.6M
National Institutes of Health (NIH)National Institutes of HealthPhase I2016$225K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Tempothera do?
Tempo Therapeutics is a biotechnology company developing therapeutics, with a focus that includes dermatology. Its team works on a pipeline built around its underlying technology platform.
Who founded Tempothera?
Tempothera was founded by Westbrook Weaver, Donald Griffin in 2014.
Who are Tempothera's investors?
Tempothera's investors include Sugati Ventures.
How much funding has Tempothera raised?
Tempothera has disclosed $20.2M raised across 2 rounds.
Where is Tempothera headquartered?
Tempothera is headquartered in San Diego, US.